Evgen Pursues Pharmaceutical Development of Sulforadex

Having recently secured substantial investment from a U.K. venture capital syndicate, Evgen Limited has exercised its option with Lalilab, Durham, NC, and PharmAgra Labs, Brevard, NC, to enter a global, exclusive license agreement to develop Sulforadex as an oral pharmaceutical. Sulforadex has demonstrated potential in the prevention of prostate cancer and other cancers, according to the companies. Lalilab and PharmAgra retain the rights to develop the patented stabilized sulforaphane technology for topical applications, focusing on skin disease therapeutics and cosmetics.